Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 48.27 CNY -4.34% Market Closed
Market Cap: 306.5B CNY
Have any thoughts about
Jiangsu Hengrui Pharmaceuticals Co Ltd?
Write Note

Jiangsu Hengrui Pharmaceuticals Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jiangsu Hengrui Pharmaceuticals Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.6B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5.2B
CAGR 3-Years
-6%
CAGR 5-Years
7%
CAGR 10-Years
6%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Pre-Tax Income
ÂĄ225.5m
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
-ÂĄ769m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Market Cap
307.9B CNY
Industry
Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals Co Ltd. is a leading player in the Chinese pharmaceutical industry, known for its strong emphasis on innovation and a commitment to enhancing patient care. Founded in 1993, Hengrui has grown rapidly, establishing itself as a key developer and manufacturer of a diverse range of medications, including oncology, analgesics, and anesthetics. The company stands out for its robust research and development framework, which has enabled it to introduce over 100 new drugs, several of which have gained global recognition. With a strategic focus on high-quality generics and innovative therapies, Hengrui caters to both domestic and international markets, positioning itself as a significant contender in the global pharmaceutical arena. Investors are particularly drawn to Hengrui's impressive financial performance and growth trajectory. The company boasts a well-established production capacity and a strong pipeline of drugs in various stages of clinical trials, which could pave the way for future revenue streams. Its commitment to compliance with international quality standards has opened doors to partnerships and market access around the world. As healthcare demands continue to rise, Hengrui's strategic investments in cutting-edge technology and expanded capabilities indicate not only resilience but also the potential for sustainable growth. With a consistent focus on innovation and a portfolio that addresses critical health needs, Jiangsu Hengrui Pharmaceuticals presents an attractive opportunity for investors looking to tap into the expanding pharmaceutical market in China and beyond.

Intrinsic Value
32.55 CNY
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Pre-Tax Income?
Pre-Tax Income
5.9B CNY

Based on the financial report for Sep 30, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd's Pre-Tax Income amounts to 5.9B CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
13%

Over the last year, the Pre-Tax Income growth was 40%. The average annual Pre-Tax Income growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -4% over the past three years , 2% over the past five years , and 13% over the past ten years .

Back to Top